How genetic variation was analyzed in phenytoin-induced gingival enlargement using single-nucleotide polymorphism of candidate gene CYP2C9?

Balakrishnan, Pachamuthu; Ramesh, Vengalathur Ganesan; Balamurali, PD; Babu, S P K Kennedy; Prasad, Karthiksree V; Gandhimadhi, D

doi:10.4103/jomfp.jomfp_273_18

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This variant can lead to reduced drug clearance, increasing the risk of adverse effects (Franco and Perucca, 2015). Similarly, a study on phenytoin-induced gingival enlargement found a homomutant presentation of the CYP2C9*2 gene, suggesting a potential role of genetic variation in this adverse effect as well (Balakrishnan, 2020).…”

Section: Anticonvulsantsmentioning

confidence: 99%

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Anunobi

2024

dujopas

View full text Add to dashboard Cite

Adverse drug reactions (ADRs) are a cause of discontinuing drug development and withdrawal from market, as well as a very common source of morbidity and mortality. Genetic variables may be the primary predictor of drug response for certain medications, but they are estimated to account for 15– 30% of the variability in drug response. Many factors can contribute to adverse drug reactions, including genetics and drug targeting/delivery. Genetic markers, such as single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes, drug targets, and human leukocyte antigen (HLA) genotypes, have been associated with an increased risk of ADRs. Pharmacogenomics is the study of the genetic variation in the way that different people react to different pharmaceuticals, including variations in the risk of adverse drug reactions, dose requirements, and efficacy. The implementation of genetic data for predicting responses to medications and ADRs is becoming a reality in clinical practice, offering the potential to reduce the incidence of ADRs and improve patient outcomes. As pharmacogenomic research continues to advance, it holds great promise for enhancing drug safety and efficacy, ultimately leading to more tailored and effective therapeutic interventions.

show abstract

Section: Anticonvulsantsmentioning

confidence: 99%

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Anunobi

2024

dujopas

View full text Add to dashboard Cite

show abstract

How genetic variation was analyzed in phenytoin-induced gingival enlargement using single-nucleotide polymorphism of candidate gene CYP2C9?

Cited by 1 publication

References 8 publications

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Contact Info

Product

Resources

About